EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia

Yongli Gu, Cong Cheng, Liqun Jiang, Daoli Jiang

Frontiers in Pharmacology · 29.04.2026 · 17

DOI: 10.3389/fphar.2026.1777708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Yongli Gu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the clinical efficacy, safety, and cost-effectiveness of nemonoxacin injection versus moxifloxacin injection in patients with community-acquired pneumonia (CAP), providing an evidence-based reference for clinical decision-making.

Methods

A retrospective cohort study was conducted, enrolling 196 patients hospitalized with CAP between January 2024 and March 2025. Based on the treatment received, patients were allocated to a nemonoxacin group (n = 103) or a moxifloxacin group (n = 93). Clinical efficacy, inflammatory markers before and after treatment, and safety outcomes were compared between the groups. A cost-minimization analysis was used for the economic evaluation.

Results

Baseline characteristics did not differ significantly between groups ( P > 0.05). Clinical efficacy was 100.0% in the nemonoxacin group versus 97.8% in the moxifloxacin group ( P = 0.135). Adverse reaction rates were 1.9% and 1.1% for nemonoxacin and moxifloxacin, respectively ( P = 0.622). Inflammatory markers decreased significantly after treatment in both groups, but the intergroup difference post-treatment was not statistically significant ( P > 0.05). The total hospitalization cost was significantly lower in the nemonoxacin group (¥6,726.31 ± 1,849.50) than in the moxifloxacin group (¥7,354.12 ± 2,477.16) ( P = 0.044), indicating superior cost-effectiveness for nemonoxacin. Sensitivity analysis supported the robustness of the economic finding.

Conclusion

Nemonoxacin malate injection demonstrates clinical efficacy and safety comparable to moxifloxacin hydrochloride injection for CAP, while incurring significantly lower treatment costs, resulting in a more favorable economic profile.

Schlagwörter

Stichwörter der Autor:innen

community-acquired pneumoniacost-minimization analysiseconomic evaluationmoxifloxacinnemonoxacin

Autor:innen und Institutionen

  • Department of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
  • School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.

Zitieren

APA

Gu, Y., Cheng, C., Jiang, L., & Jiang, D. (2026). Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1777708

Vancouver

Gu Y, Cheng C, Jiang L, Jiang D. Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1777708

BibTeX
@article{Gu2026,
  author = {Gu, Yongli and Cheng, Cong and Jiang, Liqun and Jiang, Daoli},
  title = {Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1777708}
}
Kostenlos starten →